A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

L J Aronne; S Tonstad; M Moreno; I Gantz; N Erondu; S Suryawanshi; C Molony; S Sieberts; J Nayee; A G Meehan; D Shapiro; S B Heymsfield; K D Kaufman; J M Amatruda

首页> 外文期刊>International Journal of Obesity >A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

【24h】

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

机译：一项评估taranabant，CB1R反向激动剂在肥胖和超重患者中的安全性和有效性的临床试验：一项大剂量研究

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective:To evaluate the efficacy, safety and tolerability of taranabant in obese and overweight patients.

机译：目的：评价他那班特在肥胖和超重患者中的疗效，安全性和耐受性。

著录项

来源
《International Journal of Obesity》 |2010年第5期|共17页
作者
L J Aronne; S Tonstad; M Moreno; I Gantz; N Erondu; S Suryawanshi; C Molony; S Sieberts; J Nayee; A G Meehan; D Shapiro; S B Heymsfield; K D Kaufman; J M Amatruda;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类营养学;
关键词

相似文献

外文文献
中文文献
专利

1. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study [J] . J Proietto, A Rissanen, J B Harp, International Journal of Obesity . 2010,第8期

机译：一项评估CB1R反向激动剂taranabant在肥胖和超重患者中的安全性和有效性的临床试验：低剂量研究
2. A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes [J] . M. S. Kipnes, P. Hollander, K. Fujioka, Diabetes, Obesity and Metabolism . 2010,第6期

机译：一项为期一年的研究，旨在评估CB1R反向激动剂他拉那班在2型糖尿病超重和肥胖患者中的安全性和有效性
3. A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. [J] . Kipnes MS, Hollander P, Fujioka K, Diabetes, obesity & metabolism . 2010,第6期

机译：一项为期一年的研究，旨在评估CB1R反向激动剂taranabant在2型糖尿病超重和肥胖患者中的安全性和有效性。
4. Integrating Population- and Patient-Level Data for Secondary Use of Electronic Health Records to Study Overweight and Obesity [C] . Caryn Roth, Chaitanya P. Shivade, Ri E. Foraker, MEDINFO . 2013

机译：整合人口和患者级数据进行二次使用电子健康记录，以研究超重和肥胖
5. Efficacy and safety of novel collagen conduits filled with collagen filaments to treat patients with peripheral nerve injury: A multicenter, controlled, open-label clinical trial [D] . Saeki Masaomi, 佐伯将臣 2019

机译：充满胶原细丝的新型胶原蛋白导管治疗周围神经损伤患者的疗效和安全性：一项多中心，对照，开放标签的临床试验
6. Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials [O] . Lu Ding, Bang Sun, Xinhua Xiao 2020

机译：比较胰高血糖素肽1受体激动剂与钠葡萄糖Cotroangerporter 2抑制剂的肥胖型糖尿病患者的疗效和安全性对二甲双胍的不受控制的糖尿病患者：随机临床试验的系统审查和荟萃分析
7. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study [O] . L J Aronne, S Tonstad, M Moreno, 2010

机译：评估滴答蛋白，CB1R逆激动剂，肥胖和超重患者的安全性和疗效的临床试验：高剂量研究

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

摘要

著录项

相似文献

相关主题

期刊订阅